{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:51:51Z","timestamp":1777870311344,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7759\/cureus.108034","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:41Z","timestamp":1777564361000},"source":"Crossref","is-referenced-by-count":0,"title":["FLT3 Testing and Guideline Concordance in Acute Myeloid Leukemia Across a Community Health System"],"prefix":"10.7759","author":[{"given":"Carley","family":"Yawn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Van Ravenswaay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Nisly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj J","year":"2025","unstructured":"Rataj J, Gorecki L, Muthna D, et al.. Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges. Biomed Pharmacother. 2025, 182:117788. 10.1016\/j.biopha.2024.117788","journal-title":"Biomed Pharmacother"},{"key":"ref2","unstructured":"Cancer stat facts. leukemia\u2014acute myeloid leukemia (AML). (2025). Accessed: January 26, 2026: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota S","year":"1997","unstructured":"Yokota S, Kiyoi H, Nakao M, et al.. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997, 11:1605-9. 10.1038\/sj.leu.2400812","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117089","article-title":"Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico","volume":"282","author":"Chu D","year":"2025","unstructured":"Chu D, Ji C, Zhang Y, et al.. Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico. Eur J Med Chem. 2025, 282:117089. 10.1016\/j.ejmech.2024.117089","journal-title":"Eur J Med Chem"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland DG","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002, 100:1532-42. 10.1182\/blood-2002-02-0492","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70022","article-title":"Design, synthesis, and biological activities evaluation of type I FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"85","author":"Yang J","year":"2024","unstructured":"Yang J, Zhang Y, Li YC, et al.. Design, synthesis, and biological activities evaluation of type I FLT3 inhibitors for the treatment of acute myeloid leukemia. Drug Dev Res. 2024, 85:e70022. 10.1002\/ddr.70022","journal-title":"Drug Dev Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02317.x","article-title":"FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group","volume":"111","author":"Abu-Duhier FM","year":"2000","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA, et al.. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000, 111:190-5. 10.1111\/j.1365-2141.2000.02317.x","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401777","article-title":"Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD\/SCID human chimera model","volume":"14","author":"Rombouts WJ","year":"2000","unstructured":"Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD\/SCID human chimera model. Leukemia. 2000, 14:889-97. 10.1038\/sj.leu.2401777","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120759","article-title":"The clinical utility of FLT3 mutation testing in acute leukemia: a Canadian consensus","volume":"30","author":"Bergeron J","year":"2023","unstructured":"Bergeron J, Capo-Chichi JM, Tsui H, et al.. The clinical utility of FLT3 mutation testing in acute leukemia: a Canadian consensus. Curr Oncol. 2023, 30:10410-36. 10.3390\/curroncol30120759","journal-title":"Curr Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.002","article-title":"FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myeloid leukemia","volume":"22","author":"Novatcheva ED","year":"2022","unstructured":"Novatcheva ED, Anouty Y, Saunders I, Mangan JK, Goodman AM. FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2022, 22:e161-84. 10.1016\/j.clml.2021.09.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1039\/d2md00067a","article-title":"FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms","volume":"13","author":"Acharya B","year":"2022","unstructured":"Acharya B, Saha D, Armstrong D, Lakkaniga NR, Frett B. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. RSC Med Chem. 2022, 13:798-816. 10.1039\/d2md00067a","journal-title":"RSC Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea DA","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, et al.. Acute myeloid leukemia, version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023, 21:503-13. 10.6004\/jnccn.2023.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","unstructured":"Xospata (gilteritinib) tablets, for oral use. prescribing information. (2018). Accessed: February 4, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211349s000lbl.pdf."},{"key":"ref14","unstructured":"Vanflyta (quizartinib) tablets, for oral use. prescribing information. (2024). Accessed: February 4, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216993s001lbl.pdf."},{"key":"ref15","unstructured":"Real-world treatment patterns and effectiveness of midostaurin versus quizartinib in FLT3-ITD mutated acute myeloid leukemia undergoing intensive induction. (2024). Accessed. April 13, 2025: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper205931.html."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S434556","article-title":"Treatment patterns and FLT3 mutation testing among patients with acute myeloid leukemia in China: a retrospective observational study","volume":"20","author":"Gong B","year":"2024","unstructured":"Gong B, Cheng LJ, Young CH, et al.. Treatment patterns and FLT3 mutation testing among patients with acute myeloid leukemia in China: a retrospective observational study. Ther Clin Risk Manag. 2024, 20:59-73. 10.2147\/TCRM.S434556","journal-title":"Ther Clin Risk Manag"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.406","article-title":"Rates of complete diagnostic testing for patients with acute myeloid leukemia","volume":"4","author":"Lin TL","year":"2015","unstructured":"Lin TL, Williams T, He J, et al.. Rates of complete diagnostic testing for patients with acute myeloid leukemia. Cancer Med. 2015, 4:519-22. 10.1002\/cam4.406","journal-title":"Cancer Med"},{"key":"ref18","unstructured":"ICD-10. International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd Ed. (2004). Accessed: February 4, 2026: https:\/\/iris.who.int\/handle\/10665\/42980."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456469-flt3-testing-and-guideline-concordance-in-acute-myeloid-leukemia-across-a-community-health-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:42Z","timestamp":1777564362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456469-flt3-testing-and-guideline-concordance-in-acute-myeloid-leukemia-across-a-community-health-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.108034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}